Study of Anthurium schlechtendalii Kunth Extract Effects on Nephroprotective or Renal Damage Remission Capacity

This study was aimed at investigating the nephroprotective potential of Anthurium schlechtendalii (A. schlechtendalii) Kunth root consumption as a traditional medicine for kidney disease in Mexico. Materials and Methods: Oral administration of adenine (0.75%) induced chronic kidney disease and solid and aqueous extract from plant root. These were tested at doses of 125 mg kg–1/day and 1.8 mg mL–1/day, respectively in the animal model used in 4 weeks experiment. Growth parameters, liquid consumption, 24 h urine volume, kidney weight, creatinine, creatinine clearance, blood urea nitrogen (BUN) and urine proteins were determined and also statistically recognized by variance analysis procedures (one-way ANOVA), with a post hoc Tukey multiple range test for comparison of means (p
Source: Research Journal of Medicinal Plant - Category: Complementary Medicine Source Type: research

Related Links:

Publication date: Available online 10 December 2018Source: American Journal of Kidney DiseasesAuthor(s): Christopher T. Chan, Eric Wallace, Thomas A. Golper, Mitchell H. Rosner, Rebecca Kurnik Seshasai, Joel D. Glickman, Martin Schreiber, Patrick Gee, Michael V. RoccoHome dialysis therapy, including home hemodialysis and peritoneal dialysis, is underused as a modality for the treatment of chronic kidney failure. The National Kidney Foundation–Kidney Disease Outcomes Quality Initiative sponsored a home dialysis conference in late 2017 that was designed to identify the barriers to starting and maintaining patients on h...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Publication date: Available online 10 December 2018Source: American Journal of Kidney DiseasesAuthor(s): Richard L. Amdur, Harold I. Feldman, Elizabeth A. Dominic, Amanda H. Anderson, Srinivasan Beddhu, Mahboob Rahman, Myles Wolf, Muredach Reilly, Akinlolu Ojo, Raymond R. Townsend, Alan S. Go, Jiang He, Dawei Xie, Sally Thompson, Matthew Budoff, Scott Kasner, Paul L. Kimmel, John W. Kusek, Dominic S. Raj, Jeffrey FinkRationale &ObjectiveTraditional risk estimates for atherosclerotic vascular disease (ASVD) and death may not perform optimally in the setting of chronic kidney disease (CKD). We sought to determine whether...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
Condition:   CKD Intervention:   Drug: LCZ 696 Sponsor:   The Second Affiliated Hospital of Harbin Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Kidney Diseases Intervention:   Sponsors:   Ass. Prof. Dr. Manfred Hecking, MD;   Karolinska Institutet Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   CKD Intervention:   Drug: LCZ 696 Sponsor:   The Second Affiliated Hospital of Harbin Medical University Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   Chronic Kidney Diseases Intervention:   Sponsors:   Ass. Prof. Dr. Manfred Hecking, MD;   Karolinska Institutet Active, not recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
AbstractChronic hepatitis C virus (HCV) infection is common among patients with chronic kidney disease (CKD) and those on hemodialysis due to nosocomial infections and past blood transfusions. While a majority of HCV-infected patients with end-stage renal disease are asymptomatic, some may ultimately experience decompensated liver diseases and hepatocellular carcinoma. Administration of a combination of elbasvir/grazoprevir for 12  weeks leads to high sustained virologic response (SVR) rates in patients with HCV genotypes (GTs) 1a, 1b or 4 and stage 4 or 5 CKD. Furthermore, a combination of glecaprevir/pibrentasvir fo...
Source: Hepatology International - Category: Infectious Diseases Source Type: research
We examined the prospective association between hepatitis B surface antigen (HBsAg) serolog...
Source: BMC Nephrology - Category: Urology & Nephrology Authors: Tags: Research article Source Type: research
Author Correction: Lipid management in patients with chronic kidney disease, Published online: 11 December 2018; doi:10.1038/s41581-018-0099-yAuthor Correction: Lipid management in patients with chronic kidney disease
Source: Nature Reviews Nephrology - Category: Urology & Nephrology Authors: Source Type: research
MONDAY, Dec. 10, 2018 -- Women may have a lower risk for chronic kidney disease (CKD) progression and death compared with men, according to a study published online Dec. 3 in the Journal of the American Society of Nephrology. Ana C. Ricardo, M.D.,...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
More News: Chronic Kidney Disease | Complementary Medicine | Herbs | Mexico Health | Statistics | Study | Urology & Nephrology | Weight Loss